30.31USD+0.53%Mkt Cap: 1.75B USDP/E: 12.21Last update: 2026-05-26
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAK…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap1.75B USD
Enterprise Value1.29B USD
Revenue (TTM)899.11M USD
Gross Profit670.11M USD
Net Income (TTM)158.69M USD
Revenue/Share15.60 USD
Last Price30.31 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees293
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)12.21
P/E (Forward)5.46
PEG—
EV/EBITDA6.00
EV/Revenue1.43
P/S1.96
P/B1.94
EPS (TTM)2.48
EPS (Forward)5.58
52W Range
25.5231% of range40.87
52W High40.87 USD
52W Low25.52 USD
Profitability
Gross Margin77.16%
Oper. Margin17.31%
EBITDA Margin23.90%
Profit Margin18.27%
ROE18.24%
ROA12.48%
Growth
Revenue Growth16.60%
Earnings Growth-29.50%
Cash Flow & Leverage
Operating CF348.20M USD
CapEx (TTM)310.00K USD
FCF Margin16.65%
FCF Yield8.54%
Net Debt-476.31M USD
Net Debt/EBITDA-2.22
Balance Sheet
Debt/Equity0.19
Current Ratio3.58
Quick Ratio3.45
Book Value/Sh15.73 USD
Cash/Share11.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.2 (Buy)
Target (Mean)44.36 USD
Target Range28.00 USD – 85.00 USD
# Analysts11
Ownership
Shares Out.57.89M
Float51.73M
Insiders11.69%
Institutions103.36%
Short Interest
Short Ratio8.1d
Short % Float15.96%
Short % Out.11.93%
Shares Short6.90M
Short (prev mo.)7.65M
Technical
SMA 5029.56 (+2.5%)
SMA 20032.65 (-7.2%)
Beta0.96
S&P 52W Chg28.31%
Avg Vol (30d)858.00K
Avg Vol (10d)687.94K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—